liraglutide News - LARVOL Sigma

«1 2 3 4 5 678 9 10 11 12 13...64 65 »

|||||||||| Characteristics of Glucagon-Like Peptide-1 Receptor Agonist Mentions in Unstructured Notes of Specialty Dermatology Clinics (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3670;
The percentage of unique patients with mentions increased exponentially from 2020 to 2023 (2020: 0.0010%; 2021: 0.0019%; 2022: 0.0040%; 2023: 0.0080%). Semaglutide accounted for 268 of 283 generic name mentions (95%), while the 10 GLP-1 RA trade names accounted for 1,115 mentions.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Obesity Medication Prescribing Practices in an Urban Academic Medical Center (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3663;
Patients were predominantly female, 68.3% with a mean age of 52 years; 39.1% identifying as Black and 31.5% as White, while 74.3%identified as non-Hispanic. GLP-1 receptor agonists (GLP-1 RA), semaglutide and liraglutide, were the most prescribed medications, with 82.2% of prescriptions.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Comparing the Efficacy of Endoscopic Bariatric Interventions and GLP-1 Agonists to Endoscopic Bariatric Interventions Alone in Weight Loss; A Systematic Review and Meta-analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3658;
123 patients underwent endoscopic bariatric treatment and GLP-1 agonist use combined; of these endoscopic bariatric interventions, 26 were ESG and 97 were IGB. Conversely, 143 patients underwent only endoscopic bariatric interventions alone, including 26 with ESG and 117 with IGB.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Semaglutide and Liraglutide and Incidence of New-Onset Gastroparesis, Non-Alcoholic Steatohepatitis, Acute Liver Failure, Cirrhosis, Hepatocellular Carcinoma and Mortality in Obese Diabetic Patients (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3656;
After 1:1 propensity matching, 229,454 patients were identified in semaglutide cohort and 108,395 patients were identified in liraglutide cohort. Semaglutide cohort had lower incidence of new onset gastroparesis than standard therapy cohort [OR (95% CI): 0.415 (0.405

|||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
Factors Relating to Slow Gastric Emptying on Glucagon-Like Peptide-1 Agonist Therapy, Lack of Prolonged Emptying Slowing After GLP1 Agonist Cessation, and Impact of Emptying Delays on GLP1 Agonist Prescription Patterns (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2848;
Gastric emptying was not slowed on GLP 1 RAs in the whole group (Fig 1A) but was slowed selectively in women on these meds (P=0.02). In women, emptying was similarly slowed on GLP 1 RAs given for obesity vs.

|||||||||| Gimoti (metoclopramide intranasal) / Evoke Pharma
Safety of GLP-1 Agonists With Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis: Insights From a Phase 3 Study (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2106;
Two patients who did not complete the study were in the placebo group: one discontinued after the first dose due to an abnormal EKG, and the other after five days to use a protocol-excluded allergy medication. No serious adverse events (SAEs) were reported.

|||||||||| The Role of Glucagon-Like Peptide-1 Agonists on Gastric Emptying Measured by Scintigraphy Imaging (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_2105;
We identified 10 studies on scintigraphy imaging in patients on GLP-1 agonists.(Table-1) There were 239 patients 144 patients on GLP-1 and 141 patients on placebo. The medications used were Exenatide (5), liraglutide (2), semaglutide (1), ROSE-010 (1), GLP-1 (7

|||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
GERD Outcomes in Pediatric Population With Obesity Who Received GLP-1 Agonist or Phentermine-Topiramate: A National Database Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1963;
The GLP-1 RAs group had significantly lower odds of new diagnosis of GERD (ORs, 0.18; 95% Confidence Interval [CI], 0.13-0.25) and lower odds of new PPI use (ORs, 0.78; 95% CI, 0.62-0.98). No differences were found in the incidence of new-onset asthma and the need for EGD; however, there was a tendency to favor using GLP-1 RAs.

|||||||||| Trends in the Prescription of Weight Loss Medications in Patients With Obesity: A Nationwide Cross-Sectional Analysis, 1999-2018 (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1948;
However, the use of FDA-approved drugs alone remained low ranging from 0.29% in 1999-2000 to 1.12% in 2017-2018. When anti-diabetes drugs with weight-loss effects were included, the proportion of use ranged from 5.16% in 1999-2000 to 14.24% in 2017-2018.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
GLP-1 Agonist Use is Associated With Lower Incidence of GERD, Lower Use of PPIs and Does Not Complicate GERD in Patients With Obesity Who Undergo Sleeve Gastrectomy: A National Database Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1937;
See table 1-2. The GLP-1 RAs group had significantly lower odds of new diagnosis of GERD (ORs, 0.51; 95% Confidence Interval [CI], 0.26-0.99) and lower odds of new PPI use (ORs, 0.37; 95% CI, 0.19-0.70) .

|||||||||| Weight Loss and Safety of Glucagon-like Peptide-1 Agonists in Inflammatory Bowel Disease Patients (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1355;
Patients demonstrated weight loss with GLP-1 therapy with an average weight reduction of 3.9% at the 1-year interval. 14 (12.7%) patients experienced GI side effects that led to discontinuation of GLP-1 therapy, including abdominal pain (N=2, 1.8%), bloating (N=1, 0.9%), constipation (N=4, 3.6%), diarrhea (N=4, 3.6%), gastroparesis (N=1, 0.9%), nausea (N=4, 3.6%), IBD flare (N=1, 0.9%), and pancreatitis (N=1, 0.9%).

|||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
GLP-1 Agonist Use is Associated With Lower Complications and Mortality in Patients With Ulcerative Colitis and Obesity: A National Database Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1340;
The GLP-1 RAs group had significant lower odds of all-cause mortality (ORs, 0.38; 95% Confidence Interval [CI], 0.28-0.53), lower odds of hospitalization (ORs, 0.66; 95% CI, 0.52-0.85), lower odds of intestinal complications (ORs, 0.47; 95% CI, 0.34-0.66), lower odds of corticosteroid use (ORs, 0.75; 95% CI, 0.66-0.85), and hepatobiliary manifestations ( cholangitis, bile duct carcinoma and cholelithiasis , ORs, 0.38; 95% CI, 0.23-0.63) when compared with the non- GLP -1 RAs group. No differences were found in the incidence of CRC and other extraintestinal manifestations.

|||||||||| Impact of Duration of GLP-1 Receptor Agonist Therapy in Endoscopic Outcomes (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1177;
The 249 patients previously taking a GLP1-RA before their colonoscopy were on therapy for between from less than a month to 48 months or more (Table 2). Patients from 0-6 m had an average BBPS of 6.8; 6-12m of 7.3; 12-18m of 7.07; 18-24m of 7.9; 24-30m of 6.8; 30-36m of 6.6; 36-42 of 7.4; 42-48 of 5.5; 48m or more of 6.95 (p value of 0.26).

|||||||||| Victoza (liraglutide) / Novo Nordisk
Perioperative GLP-1 Receptor Agonist Impact on Endoscopy and Colonoscopy Outcomes: A Systematic Review and Meta-Analysis (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1162;
EGD: Five observational studies revealed an increased risk of retained gastric content (RGC) in EGD with GLP-1 RAs use (OR: 4.738; 95% CI, 3.177-7.065; p< 0.001) (Figure 1-A). While two studies reported a higher risk of intubation during EGD with GLP1-RA use (OR: 4.454; 95% CI, 1.371-14.471; p=0.013) (Figure 1-B), they found no significant increase in pulmonary aspiration risk (OR: 2.093; 95% CI, 0.174-25.141; p=0.560) (Figure 1-C).

|||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Mounjaro (tirzepatide) / Eli Lilly
GLP-1 Agonists Use Is Associated With Lower Use of PPI and Do Not Worsen Outcomes in Patients With GERD: A National Database Analysis (Terrace Ballroom 1) - Aug 20, 2024 - Abstract #ACG2024ACG_462;
See table 1-2. The GLP-1 RAs group had significant lower odds of all-cause mortality (ORs, 0.18; 95% Confidence Interval [CI], 0.13-0.25) and lower odds of new PPI use (ORs, 0.78; 95% CI, 0.62-0.98) .

|||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal, IO biomarker: Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers. (Pubmed Central) - Aug 19, 2024
Interestingly, the immune-staining for tumor necrosis factor (TNF-?) was tested negative and mild positive in renal tissue of rats given Lir and/or Res while being treated with Cs A which indicated their anti-inflammatory effect that reduced the renal damage. The findings of this investigation revealed the ameliorative anti-inflammatory in addition to the antioxidant role of both liraglutide and resveratrol against the kidney damage caused due to CsA administration.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5. (Pubmed Central) - Aug 19, 2024
Liraglutide directly binds to Myo1c at arginine 93, enhancing the Myo1c/Dock5 interaction by targeting Dock5 promoter and thus promoting the proliferation, migration, and adhesion of keratinocytes. Therefore, this study provides insights into liraglutide biology and suggests it may be an effective treatment for diabetic patients with wound-healing pathologies.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline. (Pubmed Central) - Aug 18, 2024
In HK-2 cells, 5-OP significantly reduced the ELD in a dose-dependent manner through inhibiting the expression of SREBP1 and FAS. Overall, the renoprotective effect of Liraglutide in DKD rats is linked to the improvement of the gut microbiota composition and increased serum 5-OP levels, which may reduce ELD in renal tubular cells by lowering lipid synthesis.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Journal: Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists. (Pubmed Central) - Aug 16, 2024
The findings underscore the promising role of GLP-1RA in obesity management, particularly through mechanisms influencing both EI and EE. Future research should focus on systematically measuring all components of energy balance to fully elucidate the mechanisms of GLP-1RA and optimize their therapeutic use for personalized medicine.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges. (Pubmed Central) - Aug 16, 2024
Findings from ongoing clinical trials are likely to provide further insight into the possible role of anti-obesity drugs for treating BED. Since these agents can hold the potential to be misused potentiating dietary restriction and pathological weight loss, it is crucial to promote responsible prescribing practices.

|||||||||| Review, Journal: Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. (Pubmed Central) - Aug 13, 2024
Since these agents can hold the potential to be misused potentiating dietary restriction and pathological weight loss, it is crucial to promote responsible prescribing practices. No abstract available

|||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Review, Journal, HEOR, Real-world evidence, Real-world: Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care. (Pubmed Central) - Aug 12, 2024
Fortunately, during the last decade, a significant progress in pharmacotherapy of obesity has been observed, with the introduction of agents that have gained approval from regulatory authorities, namely semaglutide, liraglutide and tirzepatide, due to their impressive results in body weight reduction, alongside their beneficial, pleiotropic effects. The aim of the present review article is to discuss on evidence retrieved from real-world studies regarding the efficacy of those agents in obesity treatment, with emphasis on cost-effectiveness data, towards an effort to tackle efficiently the progression of obesity epidemic.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Journal: The Impact of Approved Anti-obesity Medications on Osteoarthritis. (Pubmed Central) - Aug 12, 2024
Liraglutide was linked to a significantly higher OA risk vs tirzepatide (HR?=?1.63, 95% CI: 1.23-2.15, p?=?0.0007). AOM use was associated with a significantly lower risk of OA and may be an effective obesity management intervention.

|||||||||| Review, Journal: Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. (Pubmed Central) - Aug 10, 2024
It is currently unclear whether the novel and promising glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptor agonists like tirzepatide and retatrutide help with BED and its comorbidities. However, these compounds have been reported to reduce binge eating in individuals with obesity or overweight.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Factors Associated with GLP-1 Agonist Use after Bariatric Surgery (159_Upper Mezzanine_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_3103;
Patients receiving GLP-1 agonists were more likely to have undergone sleeve gastrectomy and be black, female, and have a lower social vulnerability index, mirroring disparities in postoperative weight regain. Considering international shortages, understanding the demographics of this population is critical to equitable care.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Comparative Cost-Effectiveness Analysis of Bariatric Surgery and GLP-1 Receptor Agonists for the Management of Obesity (159_Upper Mezzanine_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_1695;
GLP-1RAs alone were not cost-effective. A combination of bariatric surgery and GLP-1RAs was cost-effective compared to bariatric surgery alone.

|||||||||| New trial: GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease (clinicaltrials.gov) - Aug 9, 2024
P=N/A, N=64, Not yet recruiting, Sponsor: Insel Gruppe AG, University Hospital Bern

|||||||||| Victoza (liraglutide) / Novo Nordisk
Review, Journal: Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group. (Pubmed Central) - Aug 9, 2024
A combination of bariatric surgery and GLP-1RAs was cost-effective compared to bariatric surgery alone. No abstract available

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients. (Pubmed Central) - Aug 8, 2024
No abstract available Liraglutide combined with routine therapy is effective in treating patients with diabetes, which can effectively reduce the levels of blood glucose andurinary protein, and the degree of renal fibrosis, while improving renal and immune functions and the clinical prognosis of diabetic patients.

|||||||||| Enrollment change, Trial completion date, Trial primary completion date: The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide (clinicaltrials.gov) - Aug 6, 2024
P=N/A, N=60, Recruiting, Sponsor: American University of Beirut Medical Center
Liraglutide combined with routine therapy is effective in treating patients with diabetes, which can effectively reduce the levels of blood glucose andurinary protein, and the degree of renal fibrosis, while improving renal and immune functions and the clinical prognosis of diabetic patients. N=150 --> 60 | Trial completion date: Jun 2023 --> Sep 2025 | Trial primary completion date: Jun 2023 --> Sep 2025

|||||||||| Victoza (liraglutide) / Novo Nordisk, RG7697 / Roche
Preclinical, Journal: Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice. (Pubmed Central) - Aug 5, 2024
N=150 --> 60 | Trial completion date: Jun 2023 --> Sep 2025 | Trial primary completion date: Jun 2023 --> Sep 2025 We conclude that the occurrence of H.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Effect of liraglutide in different abdominal fat layers measured by ultrasound. The importance of perirenal fat reduction. (Pubmed Central) - Aug 5, 2024
However, the maximal reduction is seen at perirenal fat, which has been recently related with hypertension and could play an important role in modulating kidney's expansion and intraglomerular pressure. US is a reproducible clinical tool to assess pathologic fat depots in patients living with obesity.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Case report: Glucagon-like peptide-1 agonists induced lipoatrophy on the face (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2835;
The most popular among them are Liraglutide and Semaglutide... The therapy with lightly reticulated with BDDA HA gel injected in a protocol of 2-3 sessions in the superficial fat compartments in the middle and lower third is a successful strategy for the treatment of GLP1 agonists induced facial lipoatrophy

|||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: Obesity in Adolescents: A Review. (Pubmed Central) - Aug 5, 2024
Intensive lifestyle modification therapy reduces BMI by approximately 3% while pharmacotherapy added to lifestyle modification therapy can attain BMI reductions ranging from 5% to 17%. Surgery is the most effective intervention for adolescents with severe obesity and has been shown to achieve BMI reduction of approximately 30%.

|||||||||| GLP-1R Agonists and Bone Health (Exhibit Halls F & G, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1641;

|||||||||| Victoza (liraglutide) / Novo Nordisk
Retrospective data, Review, Journal: Liraglutide's Effect on Weight Management in Subjects with Pre-Diabetes: A Systematic Review & Meta-analysis. (Pubmed Central) - Aug 4, 2024
While our meta-analysis suggests that liraglutide can reduce body weight, BMI, waist circumference, and HbA1c levels in individuals with pre-diabetes, the findings should be interpreted cautiously due to limitations such as the small number of trials and their short duration, and variability in dosages. Further randomized controlled trials examining long-term outcomes are essential to validate these findings and address the high heterogeneity among the studies included in this analysis.

|||||||||| Mounjaro (tirzepatide) / Eli Lilly
Journal: Switching to tirzepatide 5 mg from GLP-1 RAs: Clinical expectations in the first 12 weeks of treatment. (Pubmed Central) - Aug 4, 2024
Further randomized controlled trials examining long-term outcomes are essential to validate these findings and address the high heterogeneity among the studies included in this analysis. In this prospective study, when people with T2D on stable GLP-1 RA treatment were switched directly to tirzepatide 5

||||||||||  Victoza (liraglutide) / Novo Nordisk
Trial completion, Surgery, Bariatric surgery:  Effect of liraglutide on weight loss in patients with inadequate weight loss following bariatric surgery (EUDRACT) -  Aug 2, 2024
P4, N=48, Completed,  Sponsor: Monash University
In this prospective study, when people with T2D on stable GLP-1 RA treatment were switched directly to tirzepatide 5 Recruiting --> Completed

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension. (Pubmed Central) - Aug 1, 2024
The observation group was supplemented with liraglutide based on the control group...Multivariate Logistic regression model analysis showed that age, smoking history, drinking history, taking conventional antihypertensive drugs, taking hypoglycemic drugs, taking lipid-lowering drugs, BMI, FBG, HbA1c and LDL-C were independent influencing factors for persistent hypertension (P<0.05). GLP-1RAs could effectively improve the indexes including blood pressure, blood glucose and blood lipid in diabetic patients with hypertension.

|||||||||| Victoza (liraglutide) / Novo Nordisk
HEALING THE RIFT: A TALE OF CHEST WALL LUNG HERNIATION AND THE ODYSSEY OF CONSERVATIVE MANAGEMENT IN OBESITY IN A PATIENT WITH OBSTRUCTIVE AIRWAY DISEASE (Convention Center Exhibit Hall: Rapid Fire Area 4C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_5511;
Achieving lung healing through conservative management necessitates close clinical monitoring, optimization of airway disease control, and weight management. Patients may face recurrent hospitalizations and heightened healthcare-related risks.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Glucagon-like peptide receptor agonists and risk for depression. (Pubmed Central) - Jul 31, 2024
Patients may face recurrent hospitalizations and heightened healthcare-related risks. This study did not demonstrate a significant increase in risk for incident depression following GLP-1RA initiation.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice. (Pubmed Central) - Jul 31, 2024
Liraglutide acutely decreased body weight and blood glucose levels in association with decreases in plasma insulin and serotonin levels in food-deprived mice. These findings suggest the potential of liraglutide as a novel inhibitor of primary BAs and serotonin in the colon.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Clinical, Journal: Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder. (Pubmed Central) - Jul 31, 2024
P1/2
This manuscript describes a protocol to collect clinical data on the safety and efficacy of a GLP-1RA, liraglutide, during residential treatment of persons with OUD, laying the groundwork for further evaluation in a larger, outpatient OUD population. Improved understanding of innovative, non-opioid based treatments for OUD will have the potential to inform community-based interventions and health policy, assist physicians and health care professionals in the treatment of persons with OUD, and to support individuals with OUD in their effort to live a healthy life.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe, Trulicity (dulaglutide) / Eli Lilly
Preclinical, Journal: Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i. (Pubmed Central) - Jul 31, 2024
GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Retrospective data, Review, Journal, Surgery, Bariatric surgery: Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis. (Pubmed Central) - Jul 30, 2024
Our findings support the use of liraglutide for weight management in patients who experience weight regain after BS. Liraglutide is well tolerated and promotes significant weight loss, providing clinicians with a therapeutic option for this clinical challenge.

|||||||||| SAL0112 / Shenzhen Salubris
PK/PD data, Journal: Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112. (Pubmed Central) - Jul 28, 2024
SAL0112 demonstrated potent and selective GLP-1 receptor biased agonism, effectively alleviating signs of type 2 diabetes in a mouse model. These promising findings pave the way for the advancement of SAL0112 into clinical trials.

|||||||||| Victoza (liraglutide) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Journal: NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management? (Pubmed Central) - Jul 28, 2024
However, the recent approval of tirzepatide for obesity and T2DM, a glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor co-agonist peptide therapy, may provide a somewhat more tolerable option...However, like GLP-1 and GIP, the endogenous NPY, PYY and PP peptide forms are subject to rapid in vivo degradation and inactivation by the serine peptidase, dipeptidyl-peptidase 4 (DPP-4), and hence require structural modification to prolong circulating half-life. Numerous protective modification strategies are discussed in this regard herein, alongside related impact on biological activity profile and therapeutic promise.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Role of Brown Adipose Tissue in Metabolic Health and Efficacy of Drug Treatment for Obesity. (Pubmed Central) - Jul 27, 2024
Thereafter, patients were divided into four groups according to the type of therapy (only lifestyle modification or with Liraglutide or Reduxin or Reduxin Forte)...These drugs have the ability to increase the activity of BAT. A significant positive relationship between the total volume of BAT and the percentage of weight loss may further determine the priority mechanism of the weight-reducing effect of these medicaments.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Clinical, Journal: Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial. (Pubmed Central) - Jul 27, 2024
This study protocol hypothesizes that LNG-IUD combined with metformin and liraglutide may potentially lead to higher regression rates of endometrial hyperplasia (EH) and early stage endometrial cancer (EC) compared to LNG-IUD alone. Furthermore, the protocol anticipates that these combination therapies will demonstrate good tolerability with minimal adverse effects, suggesting the potential benefit of integrating metabolic interventions with LNG-IUD to enhance treatment efficacy while preserving fertility in women with EH and EC.

|||||||||| Victoza (liraglutide) / Novo Nordisk
Journal, Real-world evidence, Real-world: Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study. (Pubmed Central) - Jul 26, 2024
Furthermore, the protocol anticipates that these combination therapies will demonstrate good tolerability with minimal adverse effects, suggesting the potential benefit of integrating metabolic interventions with LNG-IUD to enhance treatment efficacy while preserving fertility in women with EH and EC. Liraglutide 3



	Diseases Companies Products Productz Mechanisms of Action Sites